(Reuters) – The U.S. Federal Trade Commission said it approved certain modifications to Bristol Meyers Squibb’s divestiture agreement that the FTC earlier approved and incorporated into its order as part of a consent required when the drugmaker acquired Celgene Corp in 2019.
(Reporting by Kanishka Singh in Bengaluru; Editing by Chris Reese)
